Arvinas Androgen Receptor, Inc.
Overview
Arvinas Androgen Receptor, Inc. is a subsidiary of Arvinas, Inc., which is focused on developing novel therapeutics aimed at degrading disease-causing proteins. The company leverages its proprietary PROTAC technology to target androgen receptors in the treatment of prostate cancer and other related conditions.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Arvinas Androgen Receptor, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Is this Arvinas Androgen Receptor, Inc.? Get in front of buyers actively sourcing.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.